• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eluxadoline: a promising therapy that raises many questions.

作者信息

Cash Brooks D

机构信息

Gastroenterology Division, University of South Alabama, Mobile, AL 36688, USA.

出版信息

Transl Gastroenterol Hepatol. 2016 Sep 28;1:76. doi: 10.21037/tgh.2016.09.06. eCollection 2016.

DOI:10.21037/tgh.2016.09.06
PMID:28138642
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5244598/
Abstract
摘要

相似文献

1
Eluxadoline: a promising therapy that raises many questions.依托度酸：一种引发诸多问题的有前景的疗法。
Transl Gastroenterol Hepatol. 2016 Sep 28;1:76. doi: 10.21037/tgh.2016.09.06. eCollection 2016.
2
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.关于 Eluxadoline 治疗腹泻型肠易激综合征的最新进展：患者选择和观点。
Drug Des Devel Ther. 2020 Apr 9;14:1391-1400. doi: 10.2147/DDDT.S216056. eCollection 2020.
3
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.鲁比前列酮治疗腹泻型肠易激综合征患者的安全性
Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.
4
Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.在一名无胆囊的年轻女性中由埃卢多啉诱发的复发性胰腺炎：病例报告及文献综述
Cureus. 2018 Dec 18;10(12):e3747. doi: 10.7759/cureus.3747.
5
Post-marketing reports of pancreatitis in eluxadoline-treated patients pre and post US label change.在美国标签变更前后，接受eluxadoline治疗的患者发生胰腺炎的上市后报告。
Therap Adv Gastroenterol. 2021 Apr 10;14:17562848211001725. doi: 10.1177/17562848211001725. eCollection 2021.
6
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.在对洛哌丁胺治疗反应不足的腹泻型肠易激综合征患者中，接受埃鲁索多林治疗后，患者的工作效率和健康相关生活质量得到提高。
J Manag Care Spec Pharm. 2021 Apr;27(4):469-477. doi: 10.18553/jmcp.2021.27.4.469.
7
Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.上市后病例报告显示，埃卢昔单抗相关胰腺炎发生于有/无胆囊的患者中。
Aliment Pharmacol Ther. 2018 Mar;47(6):809-815. doi: 10.1111/apt.14504. Epub 2018 Jan 19.
8
Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.患者及疾病特征对eluxadoline治疗腹泻型肠易激综合征疗效和安全性的影响：一项III期试验的亚组分析
Therap Adv Gastroenterol. 2019 Apr 15;12:1756284819841290. doi: 10.1177/1756284819841290. eCollection 2019.
9
Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.在两项3期研究中，早期反应预示着腹泻型肠易激综合征患者对eluxadoline有持续反应。
Aliment Pharmacol Ther. 2017 May;45(10):1319-1328. doi: 10.1111/apt.14031. Epub 2017 Mar 22.
10
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.在伴有腹泻的肠易激综合征患者的 2 期和 3 期研究中，埃卢昔多oline 表现出缺乏滥用潜力。
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.

引用本文的文献

1
The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy.微生物群与肠易激综合征——病理生理学、当前研究及未来治疗的综述
Front Microbiol. 2019 Jun 10;10:1136. doi: 10.3389/fmicb.2019.01136. eCollection 2019.
2
Eluxadoline in irritable bowel syndrome with diarrhea: rationale, evidence and place in therapy.埃卢多啉用于腹泻型肠易激综合征：理论依据、证据及在治疗中的地位
Ther Adv Chronic Dis. 2017 Nov;8(11):153-160. doi: 10.1177/2040622317714389. Epub 2017 Jun 21.
3
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.依鲁替尼在腹泻型肠易激综合征中的研究进展
Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7.

本文引用的文献

1
Bowel Disorders.肠道疾病
Gastroenterology. 2016 Feb 18. doi: 10.1053/j.gastro.2016.02.031.
2
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.Eluxadoline 治疗腹泻型肠易激综合征。
N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.
3
Rifaximin and eluxadoline - newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron?利福昔明和埃卢多啉——腹泻型肠易激综合征的新获批治疗药物：它们与阿洛司琼相比在临床实践中的作用是什么？
Expert Opin Pharmacother. 2016;17(3):311-22. doi: 10.1517/14656566.2016.1118052. Epub 2015 Dec 8.
4
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States.美国胃肠道、肝脏和胰腺疾病负担
Gastroenterology. 2015 Dec;149(7):1731-1741.e3. doi: 10.1053/j.gastro.2015.08.045. Epub 2015 Aug 29.
5
Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.作为一种潜在的靶向μ-δ阿片受体异聚体配体的埃卢多啉的分子特征
Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28.
6
Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care--a Rome Foundation working team report.系统评价：基层医疗中肠易激综合征的认知、诊断与管理——罗马基金会工作小组报告
Aliment Pharmacol Ther. 2014 Nov;40(10):1133-45. doi: 10.1111/apt.12957. Epub 2014 Sep 17.
7
Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.肠易激综合征与小肠细菌过度生长：是有意义的关联还是不必要的炒作。
World J Gastroenterol. 2014 Mar 14;20(10):2482-91. doi: 10.3748/wjg.v20.i10.2482.
8
The epidemiology of irritable bowel syndrome.肠易激综合征的流行病学
Clin Epidemiol. 2014 Feb 4;6:71-80. doi: 10.2147/CLEP.S40245. eCollection 2014.
9
Dietary proteins and functional gastrointestinal disorders.饮食蛋白质与功能性胃肠病。
Am J Gastroenterol. 2013 May;108(5):728-36. doi: 10.1038/ajg.2013.97. Epub 2013 Apr 9.
10
Targeted therapies for diarrhea-predominant irritable bowel syndrome.腹泻型肠易激综合征的靶向治疗
Clin Exp Gastroenterol. 2012;5:69-100. doi: 10.2147/CEG.S29023. Epub 2012 May 25.